| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 4.159 | 19.039 | 27.541 | 24.981 | 27.919 | 33.077 | 38.173 | 35.607 |
| Total Income - EUR | 0 | 0 | 4.342 | 19.621 | 28.682 | 25.389 | 28.432 | 33.747 | 38.710 | 35.694 |
| Total Expenses - EUR | 69 | 0 | 700 | 2.828 | 3.238 | 2.846 | 2.495 | 9.969 | 32.593 | 32.193 |
| Gross Profit/Loss - EUR | -69 | 0 | 3.642 | 16.793 | 25.444 | 22.544 | 25.937 | 23.778 | 6.117 | 3.501 |
| Net Profit/Loss - EUR | -69 | 0 | 3.601 | 16.600 | 25.161 | 22.294 | 25.683 | 23.454 | 5.781 | 3.180 |
| Employees | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Moldavmed Pharmaceuticals Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 103 | 102 | 33 | 0 | 0 | 29.637 | 28.980 | 55.844 | 44.277 | 28.424 |
| Current Assets | 80 | 79 | 4.264 | 21.349 | 46.303 | 21.104 | 47.418 | 6.602 | 11.912 | 13.027 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 26 | 132 | 0 | 1.323 | 1.566 | 0 | 0 | 0 |
| Cash | 80 | 79 | 4.239 | 21.217 | 46.303 | 19.781 | 45.852 | 6.602 | 11.912 | 13.027 |
| Shareholders Funds | -586 | -580 | 3.030 | 19.574 | 44.357 | 48.212 | 72.825 | 23.502 | 29.212 | 3.228 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 769 | 762 | 1.267 | 1.775 | 1.947 | 2.530 | 3.573 | 38.944 | 26.977 | 38.222 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Moldavmed Pharmaceuticals Srl